Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pyoderma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Pyoderma. Displaying page 1 of 1.
    EudraCT Number: 2008-008291-14 Sponsor Protocol Number: UKDCTN0901 Start Date*: 2009-05-14
    Sponsor Name:Nottingham University Hospitals NHS Trust
    Full Title: Study of treatments in Pyoderma Gangrenosum patients
    Medical condition: pyoderma gangrenosum
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037634 Pyoderma gangenosum LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037635 Pyoderma gangrenosum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000762-65 Sponsor Protocol Number: CAIN457ADE01T Start Date*: 2015-07-09
    Sponsor Name:Technische Universität München, School of Medicine, represented by Dean
    Full Title: Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum
    Medical condition: Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and redu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037635 Pyoderma gangrenosum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003273-21 Sponsor Protocol Number: IFX-1-P2.7 Start Date*: 2020-11-09
    Sponsor Name:InflaRx GmbH
    Full Title: Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA).
    Medical condition: Pyoderma gangrenosum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037635 Pyoderma gangrenosum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002920-41 Sponsor Protocol Number: StelaraPG01 Start Date*: 2012-01-04
    Sponsor Name:University Hospital Tübingen
    Full Title: Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients.
    Medical condition: Patients with a clinical diagnosis of Pyoderma gangrenosum
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037634 Pyoderma gangenosum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006013-11 Sponsor Protocol Number: HOTPANTS Start Date*: 2022-08-29
    Sponsor Name:Erasmus MC, department of dermatology
    Full Title: Hyperbaric Oxygen Therapy for Pyoderma gangrenosum As a New Treatment Strategy
    Medical condition: Pyoderma gangrenosum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002249-53 Sponsor Protocol Number: P150924 Start Date*: 2023-02-16
    Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP)
    Full Title: Comparing short to standard amoxicillin course for eRysipElas: a non-inferiority randomized controlled trial
    Medical condition: Adults diagnosed with lower limbs erysipelas/ cellulitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037632 Pyoderma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005754-28 Sponsor Protocol Number: PAPA-Can Start Date*: 2023-07-10
    Sponsor Name:IRCCS ISTITUTO GIANNINA GASLINI
    Full Title: A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome
    Medical condition: PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum and Acne)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    20.0 100000004850 10072225 PAPA syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001276-56 Sponsor Protocol Number: AIDA Start Date*: 2014-07-11
    Sponsor Name:North Bristol NHS - Southmead Hospital
    Full Title: A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatme...
    Medical condition: Complicated Skin and Skin Structure infections caused by Methicillin Resistant Staphylococcus Aureus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004860-78 Sponsor Protocol Number: P1209NY Start Date*: 2014-05-09
    Sponsor Name:G. Pohl-Boskamp GmbH & Co. KG
    Full Title: A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice inf...
    Medical condition: Pediculosis capitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10019199 Head pediculosis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003797-40 Sponsor Protocol Number: APD334-006 Start Date*: 2017-02-23
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations
    Medical condition: Active Skin Extra-Intestinal Manifestations in Inflammatory Bowel Disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 23:05:15 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA